(Q38327714)

2 September 2017

title

Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells (English)

1 reference

2 September 2017

X Ruan

1

1 reference

2 September 2017

H Neubauer

2

1 reference

2 September 2017

Y Yang

3

1 reference

2 September 2017

H Schneck

4

1 reference

2 September 2017

S Schultz

5

1 reference

2 September 2017

T Fehm

6

1 reference

2 September 2017

M A Cahill

7

1 reference

2 September 2017

H Seeger

8

1 reference

2 September 2017

A O Mueck

9

1 reference

2 September 2017

publication date

15 February 2012

1 reference

2 September 2017

1 reference

2 September 2017

volume

15

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

467-472

1 reference

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Differential effects of progestogens on breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Progesterone receptor membrane component 1: an integrative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

New progestagens for contraceptive use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Pharmacological profile of progestins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Pharmacology of estrogens and progestogens: influence of different routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

The Effect of Progesterone and Synthetic Progestins on Serum- and Estradiol-Stimulated Proliferation of Human Breast Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Combined oral contraceptives containing chlormadinone acetate and breast cancer: results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Breast cancer risk in postmenopausal women using estradiol-progestogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

Formation of ethinyl estradiol in women during treatment with norethindrone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13697137.2011.648232

10.3109/13697137.2011.648232

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference